代表论著 |
1.Beibei Zhang, Juan Zhang, Yaqiong Li, Na Li, Yuzhou Wang, Ru Jiang, Xiaoxia Xu, Ruifang Li, Zhenzhen Chen, Shaobo Duan*, Yongchao Wang*, and Lianzhong Zhang*.In Situ STING-Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti-PD-1-Resistant Tumors. Advanced. Materials, 2023, 2300171. (IF= 29.4) 2. Ruirui Zhang, Ruifang Li*, Lan Zhang, Ge Chen,Lianzhong Zhang*, Yongchao Wang*, Beibei Zhang*. A Dual-Mechanism Based Nutrient Partitioning Nanoregulator for Enhanced Immunotherapy against Anti-PD-1 Resistant Tumors[J]. ACS Nano, 2023, 17(14): 13461-13473. (IF= 17.1) 3.Yongchao Wang#, Ningqiang Gong#*, Chi Ma, Yuxuan Zhang, Xiaoxuan Liu*, Xing-Jie Liang*. An amphiphilic dendrimer as a light-activable immunological adjuvant (LIA) for improved in situ cancer vaccination. Nature Communications, 2021, 12(1): 4964. (IF=14.92) 4.Yongchao Wang, Jinjin Wang, Dandan Zhu,Xiaoxuan, Liu*, Xing-Jie Liang*. Effect of physicochemical properties on in vivo fate of nanoparticle-based cancer immunotherapies. Acta Pharmaceutica Sinica B, 2021, 11(4): 886-902. (IF=11.41) 5. Ningqiang Gong, Yuxuan Zhang, Xucong Teng, Yongchao Wang, Xing-Jie Liang*. Proton-driven transformable nanovaccine for cancer immunotherapy. Nature Nanotechnology, 2020, 15(12): 1053-1064. (IF= 39.21) 6. Xianlei Li, Ningqiang Gong, Falin Tian, Shangkun Zhang, Yuxuan Zhang, Yufei Wang, Guangchao Qing, Yongchao Wang, Xing-Jie Liang*. Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel[J]. Nature Biomedical Engineering, 2023, 7(9): 1129-1141. (IF= 28.1) 7. Shaobo Shan, Junge Chen, Yu Sun, Yongchao Wang, Xing-Jie Liang*. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy. Advanced science, 2022, 9, 2200353. (IF=17.52) 8. 王永超,王炳才,袁飞鹏,俞健钧,戴振亚,尤启冬等,地尔硫卓中间体α,β-三元环氧腈的合成[J]. 药学与临床研究2011,19(5)470-471. 9. 董晓阳,王子昱,王永超,戴振亚,尤启冬等,不对称小分子催化合成的最新进展及其在药物合成中的应用[J]. 中国药科大学学报2013,44(3):193-201. |